Get started
Author

D.E. Castellano Gauna

Observed names: D E Castellano Gauna, Daniel Ernesto Castellano Gauna
OpenAlex ID: A5003418753
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
2024 · Fred Saad, Egils Vjaters, et al. · Journal of Clinical Oncology · 181
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
2023 · T.B. Powles, B. Perez Valderrama, et al. · Annals of Oncology · 137
PDF
LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
2023 · O. Sartor, D.E. Castellano Gauna, et al. · Annals of Oncology · 70
PDF
LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
2025 · S.T. Tagawa, O. Sartor, et al. · Annals of Oncology · 50
PDF
LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
2024 · L. Bergmann, M. Ahrens, et al. · Annals of Oncology · 21
PDF
2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
2023 · B.E. Szabados, E. Nogueron Martinez, et al. · Annals of Oncology · 10
PDF
1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
2024 · W.K. Kelly, L.J. Appleman, et al. · Annals of Oncology · 4
1601P First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
2024 · J. Mateo, E. Castro, et al. · Annals of Oncology · 4
PDF
LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
2025 · T.B. Powles, A. Kann, et al. · Annals of Oncology · 3
PDF
2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
2023 · P. Grivas, S. Sridhar, et al. · Annals of Oncology · 3
PDF
2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)
2023 · S. Gupta, O. Alhalabi, et al. · Annals of Oncology · 3
PDF
2595MO Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment
2025 · M. Ahrens, J.B.A.G. Haanen, et al. · Annals of Oncology · 2
965P First- in- human study of the first-in-class non-cellular targeting antibody-drug conjugate (ADC), Micvotabart pelidotin (MICVO), in patients (pts) with select solid tumors
2025 · G.M. Cote, B.A. Carneiro, et al. · Annals of Oncology · 2
PDF
1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
2024 · K. Fizazi, M.J. Morris, et al. · Annals of Oncology · 2
211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
2023 · T.B. Powles, B. Perez Valderrama, et al. · Annals of Oncology · 2
PDF
1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)
2022 · B.E. Szabados, C.F. Stockem, et al. · Annals of Oncology · 2
2600MO Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer
2025 · L. Bergmann, L. Albiges, et al. · Annals of Oncology · 1
PDF
3070MO Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
2025 · A. Drakaki, S.H. Park, et al. · Annals of Oncology · 1
2366P Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
2023 · D.E. Castellano Gauna, I. Duran Martinez, et al. · Annals of Oncology · 1
PDF
1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
2023 · M. Ruiz Vico, D. Wetterskog, et al. · Annals of Oncology · 1
PDF
2393P Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC)
2023 · Y-H. Yang, C. Cubuk, et al. · Annals of Oncology · 1
1473P A prognostic microRNA-based signature for relapse risk prediction and definition of therapeutic targets in patients with high-risk localized clear cell renal cell carcinoma
2022 · A. Pinto Marin, L. Trilla, et al. · Annals of Oncology · 1
PDF
1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011
2022 · Y. Loriot, T. Csoszi, et al. · Annals of Oncology · 1
PDF
Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
2026 · S Tagawa, O Sartor, et al. · Nuklearmedizin - NuclearMedicine
2460P Patient-reported outcomes in a randomised phase I study of mevrometostat (M) plus enzalutamide (E) vs E alone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2025 · M. Schweizer, M. Calvo, et al. · Annals of Oncology
PDF
Works count: 36
Citation count: 502
H-index: 6
I10-index: 6
Year
Topic
Type